Alzheimer’s Association Launches PROTECT-Cog Prevention Trial
LONDON, United Kingdom, July 13, 2026 The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LONDON, United Kingdom, July 13, 2026 The Alzheimer’s Association has announced the launch of the PROTECT-Cog Study (Prevention of...
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
Tokyo, Japan – June 9, 2026 Kyowa Kirin Co., Ltd. has published its Integrated Report 2025, outlining the company’s...
SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...
